심막염 시장 규모, 점유율, 성장 분석 : 약제별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Pericarditis Market size was valued at USD 4.05 Billion in 2024 and is poised to grow from USD 4.33 Billion in 2025 to USD 7.27 Billion by 2033, growing at a CAGR of 6.7% during the forecast period (2026-2033).

The global market for pericarditis is experiencing steady growth driven by the rising prevalence of pericardial diseases and heightened awareness among healthcare professionals. Advances in diagnostic technologies are enhancing detection capabilities, while the adoption of targeted and transcatheter therapies is transforming treatment options. Additionally, improved access to healthcare in emerging markets and the development of clinical guidelines for early identification and management are expanding the patient base. These factors collectively support earlier intervention strategies, positioning the market for continual expansion as treatment approaches evolve and patient outcomes improve. Such dynamics make the pericarditis sector a critical area for investment and innovation within the broader healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pericarditis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pericarditis Market Segments Analysis

Global Pericarditis Market is segmented by Drugs, Route of Administration, End User, Distribution Channel and region. Based on Drugs, the market is segmented into Nonsteroidal Anti-Inflammatory Agents (NSAIDs), Steroids, Antibiotics, Colchicine and Others. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pericarditis Market

The expansion of the global Pericarditis market is significantly influenced by the rising prevalence of inflammatory cardiovascular diseases, including pericarditis. This increase can be linked to various factors, such as changes in lifestyle, the rising incidence of autoimmune disorders, and the impact of post-viral syndromes, all of which contribute to the higher occurrence of these conditions. As a result, a larger cohort of patients suffering from such inflammatory diseases necessitates advancements in diagnostic methods, specialized therapeutic options, and comprehensive long-term monitoring and management strategies, thereby intensifying demand across healthcare systems worldwide.

Restraints in the Global Pericarditis Market

The Global Pericarditis market faces significant barriers due to the frequent misdiagnosis or underdiagnosis of the condition, especially within primary care settings and areas with limited resources. This challenge arises from the absence of obvious symptoms and a general lack of awareness among healthcare providers, coupled with inadequate screening protocols. As a result, patients often experience delays in receiving appropriate care, which adversely affects health outcomes. This situation not only hampers timely interventions but also constrains the overall market potential, particularly in developing regions where healthcare awareness and resources are significantly limited.

Market Trends of the Global Pericarditis Market

The Global Pericarditis market is witnessing a notable shift towards biologic therapies, driven by the need for more effective management options for recurrent pericarditis, particularly in patients unresponsive to conventional anti-inflammatory treatments. The adoption of biologics, such as IL-1 inhibitors, is gaining traction due to their potential for improved long-term outcomes, decreased recurrence rates, and enhanced tolerability. This trend reflects a broader movement within healthcare systems across developed markets to prioritize innovative treatment modalities that address unmet medical needs. As awareness and acceptance of biologic therapies grow, their market presence is expected to expand significantly, reshaping treatment paradigms in pericarditis management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Pericarditis Market Size by Drugs & CAGR (2026-2033)

• Market Overview
• Nonsteroidal Anti-Inflammatory Agents (NSAIDs)
• Steroids
• Antibiotics
• Colchicine
• Others

Global Pericarditis Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Parenteral
• Others

Global Pericarditis Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Pericarditis Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Pericarditis Market Size & CAGR (2026-2033)

• North America (Drugs, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Drugs, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drugs, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drugs, Route of Administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drugs, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Kiniksa Pharmaceuticals, Ltd. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardiol Therapeutics (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Co. Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals USA, Inc. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cumberland Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Scilex Holding Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Par Pharmaceutical (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Azure Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Midas Pharma GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations